Thumbnail for WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight

WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight


Episode Details
Channel

All-In Podcast

Published

10/29/2026

Episode Summary

In this deep-dive episode of the All-In Podcast, host Jason Calacanis interviews Will Ahmed, the founder and CEO of Whoop, a category-defining company in the Wearables industry. Will Ahmed recounts how Whoop was born out of his physiological research as a student at Harvard in 2012, where he recognized the untapped clinical potential of measuring Heart Rate Variability 24/7. After taking 12 years to reach its first million members, Whoop experienced exponential growth—scaling to 2 million in 18 months, 3 million in 6 months, and approaching 4 million members—while amassing over 50 billion hours of continuous physiological data that form a massive Proprietary Data Moat. A pivotal strategic turning point occurred in 2018 when Whoop abandoned its $500 upfront hardware pricing—which suffered from slow consumer sales despite remarkably high user retention—and transitioned into a B2C Subscription Business priced at $15 to $30 per month with the hardware included. This shift turned Whoop into a Recurring revenue business and fundamentally altered its corporate DNA: rather than pressuring consumers into annual hardware upgrade cycles like Apple does with the iPhone and Apple Watch, Whoop became obsessed with minimizing Customer Churn, maximizing daily engagement, and shipping continuous software innovations (such as AFib detection, Advanced Labs blood work, and Healthspan metrics) on top of existing hardware in the field. Jason Calacanis, who has tested nearly every device in the market including Fitbit, Oura, and the Apple Watch alongside Apple Health—and remarks on how foolishly Nike exited the wearable hardware space early on—endorses Whoop and Eight Sleep as his two favorite health products. Thanks to its screenless form factor, waterproof design, 14-day battery life, and slide-on battery pack, members wear Whoop an average of 23.6 hours per day. The software centers on three core pillars: Sleep, the Whoop Recovery Score, and the Whoop Strain Score, underpinned by continuous monitoring of respiratory rate, skin temperature, blood oxygen, Resting Heart Rate, and Heart Rate Variability. Will Ahmed explains how Heart Rate Variability reflects the balance between the sympathetic and parasympathetic branches of the autonomic nervous system and serves as a crucial indicator of Longevity, since fighting the natural age-related decline in HRV signals superior cardiovascular fitness. Both host and guest highlight how continuous baseline tracking is transforming Preventative Health: Jason Calacanis shares how elevated respiratory rate and skin temperature on Whoop alerted him two days before an emergency room visit for chest and lung inflammation, and previously helped him detect COVID-19 early enough to get Paxlovid the same day, while Will Ahmed recounts how members caught stage four Hodgkin's lymphoma and testicular Cancer early after noticing sudden spikes in sleeping heart rate or plummeting HRV baselines. To connect biometrics with daily habits, over 50% of members use the Whoop Journal every day to log more than 100 behaviors—revealing insights such as the severe negative recovery impact of alcohol and eating within three hours of bedtime, or the +7% recovery boost Jason Calacanis gets from warm salt baths. Furthermore, 80% of members interact with the Whoop AI Coach, which synthesizes sensor data, journal logs, and travel schedules to deliver tailored guidance. Internally, Whoop is training its own Foundational Models on physiological data, uploaded medical records, and blood tests to pioneer non-invasive Biomarker Prediction, aiming to predict when biomarkers like cortisol are out of range without drawing blood. They also discuss Whoop's newly launched tracker for GLP-1s, which Jason Calacanis uses after losing 43 pounds; the feature coaches users on daily steps, hydration, protein intake, and resistance training to prevent the 50% lean Muscle loss typically associated with GLP-1 weight loss. Turning to regulation, Will Ahmed details Whoop's complex relationship with the FDA: while Whoop went through clinical trials to secure FDA 510k Clearance for its medical-grade wrist ECG feature, it engaged in a public dispute with the FDA after launching cuffless Blood Pressure Insights—trained via a 70,000-member study and calibrated with cuffs like Omron—as a wellness feature, which ultimately prompted the FDA to update its regulatory guidelines to recognize wellness applications for blood pressure. Following a lightning round in which Will Ahmed compares health influencers Bryan Johnson and Andrew Huberman and favors traditional hot Sauna therapy over red light therapy, Will Ahmed announces that LeBron James—one of the first 100 people to wear Whoop organically 11 years ago—has officially signed on as a global ambassador, joining Cristiano Ronaldo and Patrick Mahomes. They examine the evolving rules around wearing sensors in professional sports, including ongoing evaluations by the NBA and a controversy at the Australian Open where tennis players were asked to remove their bands despite prior approval from the International Tennis Federation. Finally, Jason Calacanis and Will Ahmed close by discussing late-stage venture capital dynamics, the importance of getting CFO approval when structuring SPVs, navigating broker fishing expeditions in Secondary Markets, syndicating late-stage deals like Zipline, and Jason Calacanis's early experience selling 10% of his Uber shares to Masayoshi Son.

Investment Ideas
2 ideas
2 medium confidence

This episode features a deep dive into Whoop, a wearable health technology company. The discussion highlights Whoop's transition to a subscription model, its extensive proprietary health data, and its innovative use of AI for personalized health insights. It also touches upon the evolving landscape of wearable technology, regulatory challenges with the FDA, and the growing importance of physiological data in preventative health and longevity.

Portfolio lens: A basket of companies leveraging proprietary data and subscription models to disrupt traditional industries, with a focus on health and wellness technology.

Generated with gemini-2.5-flash-lite on 11/1/2026, 5:57:18 AM. For research only. Not financial advice.
Whoop's Data Moat and Subscription Model
medium confidence
Public Equity
Time horizon: Long-term, due to the network effects of data accumulation and the sticky nature of subscription models in health tech.
Thesis

Whoop's subscription-based model, coupled with its vast proprietary health data, creates a strong competitive advantage and recurring revenue stream, positioning it for continued growth in the preventative health market.

Rationale

The episode details Whoop's successful pivot from a one-time hardware purchase to a subscription model, which significantly improved engagement and customer retention. The CEO emphasizes the 50 billion hours of continuous physiological data collected, forming a 'proprietary data moat' that fuels AI-driven insights and product innovation.

Evidence
  • Whoop transitioned from a $500 upfront hardware fee to a $15-$30/month subscription model in 2018.
  • The company scaled from 1 million to 4 million members, accumulating over 50 billion hours of continuous physiological data.
  • The subscription model shifted the company's DNA to obsess over minimizing customer churn and maximizing daily engagement.
  • Innovation now focuses on software updates on existing hardware, adding features like AFib detection, advanced labs, and Healthspan metrics.
Catalysts
  • Continued growth in member base and data accumulation.
  • Successful development and deployment of new AI-driven health insights and features.
  • Expansion into new markets or demographic segments.
  • Potential for strategic partnerships or M&A activity in the health tech space.
Risks
  • Increasing competition from established tech giants (e.g., Apple, Google) and other wearable startups.
  • Potential for regulatory changes impacting health data collection and usage.
  • Sustaining high customer engagement and preventing churn in a competitive market.
  • Reliance on continued hardware innovation to support the subscription service.
Next Diligence
  • Analyze Whoop's latest financial filings for revenue growth, churn rates, and profitability.
  • Assess the competitive landscape and market share of key wearable health tech players.
  • Evaluate the roadmap for Whoop's AI development and new feature releases.
  • Monitor regulatory developments related to wearable health devices and data privacy.
Whoop
Apple
Apple Watch
Fitbit
Oura
Eight Sleep
Google Health
Nike
Preventative Health and Biomarker Prediction via Wearables
medium confidence
Technology Watchlist
Time horizon: Medium-term, as AI capabilities mature and regulatory frameworks adapt to these new health insights.
Thesis

Continuous physiological monitoring from wearables like Whoop is enabling early detection of health issues and predictive insights into biomarkers, transforming preventative healthcare.

Rationale

The episode provides compelling anecdotes of Whoop users detecting serious health conditions like lung inflammation, COVID-19, Hodgkin's lymphoma, and testicular cancer early due to abnormal physiological signals. The CEO discusses the potential to predict biomarker levels (e.g., cortisol) without direct measurement, leveraging foundational models trained on extensive physiological and user-logged data.

Evidence
  • Jason Calacanis was alerted to elevated respiratory rate and skin temperature by Whoop before experiencing chest pain, leading to a diagnosis of lung inflammation.
  • Whoop alerted a user to elevated heart rates during sleep, leading to the early detection of stage four Hodgkin's lymphoma.
  • Another member's plummeting HRV baseline led to the early diagnosis of testicular cancer.
  • Whoop is training foundational models on physiological data, blood tests, and medical records to pioneer non-invasive biomarker prediction.
  • The Whoop AI Coach synthesizes sensor data, journal logs, and schedules to provide tailored guidance.
Catalysts
  • Advancements in AI and machine learning applied to physiological data.
  • Increased adoption of wearables for continuous health monitoring.
  • Validation of predictive biomarker insights through further research and clinical studies.
  • Integration of wearable data with electronic health records (EHRs).
Risks
  • Accuracy and reliability of AI-driven predictions and early detection.
  • Regulatory hurdles for features moving from wellness to medical diagnostics.
  • User privacy concerns regarding the collection and use of sensitive health data.
  • Potential for over-reliance on technology, leading to false positives or missed diagnoses.
  • The challenge of translating correlations into causal relationships for health interventions.
Next Diligence
  • Investigate the scientific literature on HRV and other physiological signals as early indicators of disease.
  • Research the development and validation of AI models for biomarker prediction in healthcare.
  • Examine the regulatory pathways for wellness devices offering medical insights.
  • Track the adoption and effectiveness of AI coaches in wearable health devices.
Whoop
Heart Rate Variability (HRV)
AI
Foundational Models
Biomarker Prediction
FDA
GLP-1s
Omron
Watchlist
  • Whoop member growth rate
  • Whoop churn rate
  • FDA regulatory decisions on wellness devices
  • Advancements in AI for physiological data analysis
  • Adoption of GLP-1 tracking features
  • New partnerships or ambassador announcements for Whoop
Open Questions
  • What is the long-term impact of continuous physiological monitoring on healthcare costs and outcomes?
  • How will the regulatory landscape evolve to accommodate AI-driven health insights from wearables?
  • What are the ethical considerations of using AI to predict health conditions based on wearable data?
  • Can Whoop maintain its competitive edge against larger tech companies entering the health wearable space?
  • What is the potential for Whoop's data moat to be leveraged for drug discovery or clinical trial recruitment?
Key Topics & People
Harvard
Harvard
Organization

University where Will Ahmed studied, researched continuous heart rate variability, and founded Whoop in 2012.

Founder and CEO of SoftBank who pressured early Uber investors to sell secondary shares by threatening to invest in rival Lyft.

Uber
Uber
Organization

Global ride-sharing giant where Jason Calacanis was an early investor and sold 10% of his stake in a secondary transaction to SoftBank.

Zipline
Organization

Autonomous drone delivery unicorn that Jason Calacanis's syndicate invested in via a late-stage SPV with CFO approval.

Private equity markets where existing shareholders, employees, and early investors sell private startup shares prior to an IPO, often targeted by secondary brokers fishing for deals.

SPVs
Topic

Special Purpose Vehicles used by venture syndicates and investors to pool capital for late-stage private company investments and secondary share purchases.

Governing body of world tennis (ITF) that officially approved Whoop wearables to be worn by athletes during competitive matches.

Grand Slam tennis tournament that controversially ordered players to remove their Whoop bands during match play despite prior federation approval.

NBA
Organization

The National Basketball Association, which is actively evaluating rules around allowing players to wear screenless biometric sensors during live games.

Championship NFL quarterback and global ambassador for Whoop.

Global soccer icon who organically adopted Whoop before becoming an investor and global brand ambassador.

Legendary NBA basketball player who wore Whoop organically for 11 years as one of its first 100 users before becoming an official global ambassador.

Sauna
Sauna
Technology

Traditional high-heat therapy favored by Will Ahmed for longevity and contrast therapy over red light therapy.

Neuroscientist and health podcaster credited by Will Ahmed for bringing science and actionable health protocols to a massive global audience.

Longevity entrepreneur known for extreme biomarker measurement and anti-aging protocols.

Eight Sleep
Eight Sleep
Organization

Smart mattress cover and sleep fitness company that Jason Calacanis invested in and endorses alongside Whoop as his top two health products.

Nike
Nike
Organization

Global athletic apparel giant that entered the wearable hardware market early on before abandoning the category and handing its momentum to Fitbit.

Oura
Oura
Organization

Maker of the Oura smart ring, a wearable competitor tested by Jason Calacanis before he settled on Whoop.

Fitbit
Fitbit
Organization

Early pioneer in consumer fitness wearables, now part of Google Health, that absorbed Nike's wearable efforts.

Apple Health
Technology

Apple's health data aggregation software platform, which Jason Calacanis criticizes for poor usability and awkward third-party device syncing.

Apple Watch
Apple Watch
Technology

The world's most popular smartwatch, criticized by Jason Calacanis for constant notification distractions and short battery life compared to screenless wearables.

Apple
Apple
Organization

Consumer technology giant that manufactures the iPhone and Apple Watch, relying on annual hardware upgrade cycles to drive revenue.

Omron
Organization

Medical electronics manufacturer known for blood pressure cuffs, mentioned by Jason Calacanis as an integration partner for calibration or a potential acquisition target for Whoop.

Official medical device regulatory clearance granted by the FDA, which Whoop obtained through clinical trials for its wrist-based ECG and AFib detection feature.

Whoop's cuffless wrist-based blood pressure tracking capability developed from a 70,000-member study that sparked a regulatory dispute over wellness vs. medical device classification.

FDA
PoliticalEntity

The US Food and Drug Administration, which regulates medical devices and clashed publicly with Whoop before updating its wellness guidelines to permit blood pressure insights.

A major clinical drawback of GLP-1 weight loss where roughly 50% of lost weight comes from muscle tissue unless mitigated by resistance training and adequate protein intake.

GLP-1s
Technology

Weight-loss and metabolic medications tracked via a dedicated Whoop feature to help users manage side effects, maintain hydration, and preserve lean muscle mass.

The pursuit of extending healthspan and lifespan, supported on Whoop through features like Whoop Age, strength training, and preventing age-related HRV decline.

Cancer
Cancer
Topic

Life-threatening malignancies, including stage four Hodgkin's lymphoma and testicular cancer, that Whoop members caught early due to sudden anomalies in sleeping heart rate and HRV baselines.

Respiratory viral infection that Jason Calacanis detected early after Whoop alerted him to two consecutive days of elevated skin temperature and abnormal HRV.

Preemptive detection of acute illnesses and chronic conditions before clinical symptoms fully manifest, enabled by continuous 24/7 baseline biometric monitoring.

Biomarker Prediction
ScientificConcept

The emerging capability to predict whether blood biomarkers (such as cortisol) are out of range purely by analyzing continuous non-invasive physiological signals from the wrist.

Large-scale machine learning models trained internally by Whoop on top of its 50 billion hours of continuous physiological data, blood tests, and medical records.

Whoop AI Coach
Technology

A conversational AI assistant built into the Whoop app and used by 80% of members that synthesizes physiological data, journal entries, and goals to deliver personalized coaching.

Whoop Journal
Technology

An interactive feature used by over 50% of Whoop members every day to log over 100 lifestyle behaviors, supplements, diets, and habits to quantify their impact on recovery.

A daily metric on Whoop that quantifies the cardiovascular and muscular load placed on a user's body through exercise and daily stressors.

A daily 0 to 100% color-coded (red, yellow, green) metric indicating how ready a member's body is to perform and take on cardiovascular or mental strain.

Sleep
Sleep
Topic

One of Whoop's three core physiological pillars, measuring sleep consistency, hours of quality sleep vs. time in bed, slow-wave sleep, REM sleep, and circadian rhythm.

The number of times the heart beats per minute while at complete rest, tracked continuously by Whoop to monitor cardiovascular fitness and detect acute health anomalies.

Heart Rate Variability
ScientificConcept

The variation in time intervals between successive heartbeats (HRV), serving as a direct lens into the autonomic nervous system, recovery readiness, and long-term longevity.

The rate at which subscribers cancel their memberships, a critical metric that shifts a subscription company's focus toward continuous software innovation and member retention.

Predictable, ongoing revenue stream generated via subscriptions, which unlocked rapid growth for Whoop and increased its appeal to investors.

Business model adopted by Whoop in 2018 where the hardware sensor is included in a $15 to $30 monthly membership rather than sold for a $500 upfront fee.

Whoop's massive competitive advantage built on over 50 billion hours of 24/7 continuous physiological data combined with lab results and daily user behavior logs.

Wearables
Technology

Category of body-worn smart sensor devices designed to continuously track physiological metrics, fitness, recovery, and sleep.

All-In Podcast
Organization

Technology, business, and investing podcast hosting the in-depth interview with Will Ahmed.

Host of the All-In Podcast and This Week in Startups, early-stage and late-stage venture investor, and dedicated Whoop user.

Whoop
Organization

A wearable technology and health subscription company founded in 2012 that has scaled to nearly 4 million members and collected over 50 billion hours of continuous physiological data.

Founder and CEO of Whoop, who started the wearable technology company in 2012 after conducting physiological research at Harvard.